Prevention of diabetes in the non-obese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysaccharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae

Diabetes and Metabolism

Volumn 22, Issue 5, 1996, Pages 341-348

  Sai P ^a   Rivereau, A S ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Diabetes; Glycoprotein extracts; Insulin; Lipopolysaccharide; NOD mice; Oral administration; Prevention

Indexed keywords

BIOSTIM; CYCLOPHOSPHAMIDE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOSTIMULATING AGENT; INSULIN; KLEBSIELLA PNEUMONIAE GLYCOPROTEIN; UNCLASSIFIED DRUG; CYCLOSPORIN; GLYCOPROTEIN; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; ADOPTIVE TRANSFER; ANIMAL; BLOOD; DRUG EFFECT; ESCHERICHIA COLI; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KLEBSIELLA PNEUMONIAE; LYMPHOCYTE TRANSFUSION; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PATHOLOGY; SPLEEN; TRANSPLANTATION;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; BLOOD GLUCOSE; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; ESCHERICHIA COLI; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; KLEBSIELLA PNEUMONIAE; LIPOPOLYSACCHARIDES; LYMPHOCYTE TRANSFUSION; MICE; MICE, INBRED NOD; RECOMBINANT PROTEINS; SPLEEN;

EID: 0029661838     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Castano L, Eisenbarth GS. Type I diabetes: a chronic auto-immune disease of man, mouse and rat. Annu rev Immunol, 1990, 8, 647-750.
2. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol. Today, 1994, 15, 115-117.
3. Pozzilli P, Dupré J. New intervention modalities for the prevention of insulin-dependent diabetes. Diab Nutr Metab, 1995, 8, 69-73.
4. Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin dependent diabetes. Diabetes Metab Rev, 1993, 9, 279-287.
5. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice are reduced by prophylactic insulin therapy. Diabetes, 1990, 39, 933-937.
6. Godfredson GF, Buschard K, and Frandson EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia, 1985, 28, 933-935.
7. Keller RJ, Eisenbarth GS and Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet, 1993, 341, 927-928.
8. Weiner HL, Friedman A, Miller A, Khourty SJ et al. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific auto-immune diseases by oral administration of autoantigens. Annu Rev Immunol, 1994, 12, 809-837.
9. Trentham D, Dynesius-Trentham R, Orav E. Effects of oral administration of collagen on rheumatoid arthritis. Science, 1993, 12, 809-837.
10. Weiner H, Mackin, Matsui M. Double blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science, 1993, 259, 1321-1324.
11. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in non obese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA, 1991, 88, 10252-10256.
12. Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun, 1994, 7, 655-663.
13. Khoury S, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental auto-immune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med, 1992, 176, 1355-1364.
14. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-β, and prostaglandin-E. Am J Pathol, 1995, 147, 1193-1199.
15. Zhang JZ, Shoelson S, Miller A, Weiner HL. Insulitis is suppressed in NOD mice by oral administration of insulin peptides and glucagon. FASEB, 1992, 6, 1693-1697.
16. Harada M and Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia, 1984, 27, 604.
17. Yasunami R and Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol, 1988, 18, 481.
18. Khoury S, Lider O, Al-Sabbagh A, Weiner HL. Suppression of experimental auto-immune encephalomyelitis by oral administration of myelin basic protein III. Synergistic effect of lipopolysaccharide. Cell Immunol, 1990, 131, 302-310.
19. Wicker LS, Miller BJ and Mullen Y. Transfer of auto-immune diabetes mellitus with splenocyte from nonobese diabetic (NOD) mice. Diabetes, 1986, 35, 855.
20. Martignat L, El Mansour A, Audrain M, Julien JF, Charbonnel B, Saï P. Pancreatic expression of antigens for islet cell antibodies in non-obese diabetic mice. Journal of Autoimmunity, 1995, 8, 465-482.
21. Senecat O, Martignat L, Elmansour A, Audrain M, Julien JF and Saï P. Diabetes enhancement of diabetes and increased islet antigen expression in NOD mice following neonatal injections of glucose and arginine. Metabolism, 1994, 43, 1-10.
22. Saï P, Damgé C, Rivereau AS, Hoeltzel A, Gouin E. Prophylactic oral administration of metabolocally active insulin entrapped into isobuthylcyanoacrylate nanocapsules reduces the incidence of diabetes in NOD mice. J Autuimm (submitted), 1996.
23. Chaillous L, Darquy S, Maugendre S, Rivereau AS, Reach G, Saï P. Xenografts of porcine islets immunoprotected in hollow fibres reduce the incidence of diabetes in NOD mice. Diabetologia, 1996, 39, 523-529.
24. Serreze DV, Leiter EH, Kuff EL, Jardieu P and Ishizaka K. Molecular mimicry between insulin and retroviral antigen p73: development of cross-reactive autoantibodies in sera of NOD and C57BL/KsJ db/db mice. Diabetes, 1988, 37, 351-358.
25. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol, 1994, 24, 1853-1857.
26. Ziegler AG, Vardi P, Ricker AT, Hattori M, Soeldner JS, Eisenbarth GS. Radioassay determination of insulin autoantibodies in NOD mice: correlation with increased risk of progression to overt diabetes. Diabetes, 1989, 38, 358-363.
27. Lefrançois L. Extrathymic differentiation of intraepithelial lymphocytes: generation of a separate and unequal T-cell repertoire? Immunol Today, 1991, 12, 436-438.
28. Liu LM, MacPherson GG. Antigen acquisition by dendritic cells: intestinal dendritic cells acquire antigen administred orally and can prime naive T cells in vivo. J Exp Med, 1993, 178, 1299-1307.
29. Camerini V, Panwala C, Kronenberg M. Regional specialization of the mucosal immune system. Intraepithelial lymphocytes of the large intestine have a different phenotype and function than those of the small intestine. J Immunol, 1993, 151, 1765-1776.
30. Liblau RS, Singer SM and McDevitt HO. Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific auto-immune diseases. Immunol Today, 1995, 34, 34-38.
31. Muir A, Peck A, Clare-Salzer M, Song YH, Cornelius J, Luchetta R, Krischer J, Maclaren N. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest, 1995, 95, 628-634.
32. Gladstone P, Nepom GT. The prevention of IDDM Injecting insulin into the cytokine network. Diabetes, 1995, 44, 859-862.
33. McInerney MJ, Pek SB, Thomas DM. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes, 1991, 40, 715-725.
34. Shehadeh NN, Calcinaro F, Bradley BJ, Bruchlim I, Vardi P, Lafferty KJ. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet, 1994, 343, 706-907.
35. Shehadeh NN, La Rosa F, Lafferty KJ. Altered cytokine activity in adjuvant inhibition of auto-immune diabetes. J Autoimmunity, 1993, 6, 291-300.
36. Sadelain MWJ, Qin HY, Lauzon J, Singh B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes, 1990, 39, 583-589.
37. Kato K, Yamamoto KI, Kimura T. Migration of natural suppressor cells from bone marrow to peritoneal cavity by live BCG. J Immunol, 1985, 135, 3661-3668.
38. Campbell IL, Kay TWH, Oxbrow L, Harrison LC. Essential role for interferon-gamma and interleukin-6 in auto-immune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest, 1991, 87, 739-743.
39. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in the nonobese diabetic mouse. J Exp Med, 1993, 178, 87-99.
40. Rothe H, Schade U, Kleemann R, Bosse G, Hibino T, Martin S and Kolb H. Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia, 1994, 37, 1154.
41. Saï P, Rivereau AS, Granier C, Haertlé T, Martignat L. Immunization of nonobese diabetic mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide-accelerated diabetes. Clin Exp Immunol, 1996, 105, (in press).
42. Pozzilli P, Signore A, Williams AJK, Beales PE. NOD mouse colonies around the world recent facts and figures. Immunol Today, 1993, 14, 193-196.
43. Visalli N, Boccuni ML, Baroni MG, Buzzetti R, Nistico E, Mesturino C, Signore A, Cavallo MG, Andreani D, Lucentini L, Matteoli MC, Crino CA, Teodonio C, Amoretti R, Paci F, Ruggeri M, Pisano L, Pennafina MG, Suraci C, Santopadre G, Boscherini B, Stoduto S, Fonte MT, Batelli F, Multari G, Campea L, Suppa MA, De Mattia GC, Cassone Faldetta M, Marozzi G, Mancini A, Testa G, Marietti G, Ponte E, Perrone F, Bizzari C, Greco AV, Ghirlanda G and Pozzilli P (the IMDIAB Group). BCG vaccine and nicotinamide in recent onset IDDM: a randomized multicenter study. Autoimmunity, 1995, 21, A278.